Our Senior Executives

About Our Executives

In addition to the Board of Directors, our Senior Executive Team, or SET, is the body through which our Chief Executive Officer (CEO) exercises the authority delegated by the Board. Our CEO leads the SET and has executive responsibility for the management, development and performance of the business. The CEO, Chief Financial Officer and SET also take the lead in developing our strategy for review, constructive challenge and approval by the Board as part of our annual strategy review process.

Linda Zuckerman, Ph.D.

President & C.E.O

LinkedIn
Linda Zuckerman, Ph.D. has over 15 years in bringing novel protein therapeutics, pharmaceuticals, and medical devices from R&D to clinical trials and on to licensure at the FDA, EMA, and other agencies with regulatory authority. She has secured the approval of several biologics and medical devices and her experience crosses a wide range of indications for use including: oncology, autoimmunity, and hemostasis.
Dr. Zuckerman will now bring her extensive drug development expertise to the global health problem of antibiotic resistance through her work at ID Genomics as the President and CEO, with the ultimate goal of realizing rapid, point-of care, diagnostic technologies to enable accurate prescribing habits for antibiotics across a wide range of microbial infections. She was previously the CEO of Xcede Technologies, Inc. and President of ProFibrix Inc. prior to joining ID Genomics. Her tenure also includes leadership and scientific positions at ZymoGenetics and Genentech Inc.

Elena Rechkina, Ph.D.

Director of Lab Operations

LinkedIn
Dr. Rechkina has an extensive experience and broad scientific background in Molecular biology and has worked for over 7 years in industrial R&D of PCR diagnostics and production quality control.
For the last six years she has been with the Department of Microbiology, University of Washington, Seattle, and ID Genomics, where she became a leader in the qPCR-based clonotyping, whole genome sequencing and analysis, single nucleotide polymorphism detection and multi locus sequence typing.

Sandy Ryan, RAC

Director for Administrative and Quality Assurance/Regulatory Affairs
LinkedIn
Ms. Ryan has over 12 years of experience in all phases of accounting, including but not limited to administration of government grants and yearly and quarterly financial implementation and oversight of quality and regulatory systems for a small IVD manufacturer; including development of Design History Files, Technical Files, Document control system, Device Master records, and lead for FDA Inspections and ISO 13485 Audits.

Veronika Tchesnokova, M.D., Ph.D.

Director of Research and Development

LinkedIn
Dr. Tchesnokova’s work includes the development and implementation of the study designs, reporting, overseeing the data integrity and quality control measures, statistical analysis of clinical and experimental data and providing counsel on all scientific engagements of the organization. Dr. Tchesnokova’s is also a research scientist in Microbiology at the University of Washington – School of Medicine. She has co-authored 59 peer-reviewed publications.

Also Meet Our Board

Board of Directors